ENXTPA:SANPharmaceuticals
Dupixent’s AFRS Approval Adds Depth To Sanofi’s Specialty Care Story
Sanofi’s Dupixent has received US FDA approval for treating allergic fungal rhinosinusitis, the first targeted biologic cleared for this condition.
The approval covers both adult and pediatric patients, offering a new option where standard therapies often fall short.
This decision expands Dupixent’s label within respiratory and immunology care and reinforces Sanofi’s focus on specialty medicines.
For investors watching ENXTPA:SAN, this approval arrives at a time when the share price is...